BMP7 and acute kidney injury: Although the primary outcome was development of acute kidney injury within 7 days of cardiac surgery, a randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of THR-184, a BMP-7 mimetic peptide, in patients who received cardiac surgery requiring cardiopulmonary bypass with additional risk factors for acute kidney injury [57].